Breaking News Instant updates and real-time market news.

AIMT

Aimmune

08:09
11/28/16
11/28
08:09
11/28/16
08:09

Aimmune announces global enrollment completion of phase 3 AR101 PALISADE trial

Aimmune Therapeutics announced it has completed global enrollment of its Phase 3 PALISADE trial of AR101 for the treatment of peanut allergy, with the total randomized to the trial expected to be approximately 540 patients. AR101 is Aimmune's investigational biologic oral immunotherapy for desensitization of patients with peanut allergy. Aimmune continues to expect topline data from PALISADE in 4Q17, followed by regulatory submissions for marketing approval of AR101 in 2018 in both the U.S. and Europe. The company announced completion of North American enrollment in PALISADE in September, ahead of schedule and above target enrollment. Aimmune also announced ARTEMIS, a new dedicated European clinical trial of AR101 in peanut-allergic children and adolescents. ARTEMIS is designed to expand the data available on the efficacy profile of AR101 by exploring a higher level of protection after a shorter treatment period in a broader group of patients than in PALISADE. The primary efficacy endpoint in this new trial will be tolerating a cumulative amount of 2,043 mg of peanut protein in an exit double-blind, placebo-controlled food challenge after approximately nine months of treatment with AR101. ARTEMIS is a randomized, double-blind, placebo-controlled trial in peanut-allergic children and adolescents ages 4-17. The inclusion criteria for the trial will allow for baseline toleration of a cumulative amount not exceeding 144 mg of peanut protein in an entry DBPCFC. Patients will undergo approximately six months of up-dosing and then three months of maintenance therapy at 300 mg of AR101 per day, followed by an exit DBPCFC. Aimmune expects ARTEMIS to enroll between 120 and 160 patients at multiple sites in Europe, beginning in mid-2017.

  • 29

    Nov

  • 01

    Dec

  • 14

    Dec

AIMT Aimmune

06/28/16
PIPR
06/28/16
NO CHANGE
Target $38
PIPR
Overweight
Piper reiterates Overweight on Aimmune after management meetings
After hosting meetings with management, Piper Jaffray analyst Charles Duncan reiterates an Overweight rating on Aimmune Therapeutics (AIMT) with a $38 price target. The stock closed yesterday down 44c to $11.01 and is down over 40% year-to-date. No matter how the Phase II data is dissected, Aimmune's AR101 appears to produce a higher response rate in about 50% less time than DBV Technologies' (DBVT) Viaskin, Duncan tells investors in a research note. He believes investors may be overlooking future potential drivers of competitive advantage for AR101.
08/23/16
PIPR
08/23/16
NO CHANGE
PIPR
Aimmune data positive, says Piper Jaffray
Piper Jaffray analyst Charles Duncan says that a study of Aimmune's OIT in very young children with peanut allergies indicates that it provides "clinically meaningful protection and perhaps even a disease modifying effect." The analyst says that the drug demonstrated "unexpectedly good" tolerability, and he believes that the data indicates that the drug could be differentiated versus the current standard of care. He keeps a $38 price target and Overweight rating on the stock.
09/21/16
PIPR
09/21/16
NO CHANGE
Target $38
PIPR
Overweight
Aimmune enrollment completion a 'big positive,' says Piper Jaffray
Piper Jaffray analyst Charles Duncan calls Aimmune Therapeutics' announcement yesterday that it completed North American enrollment of 350 patients in its Phase III PALISADE trial of AR101 as a "big positive." The faster than expected timelike "speaks to the unmet need in peanut allergy across the differentiated, broad patient population enrolled in PALISADE, Duncan tells investors in a research note. The analyst reiterates an Overweight rating on the shares with a $38 price target.
09/26/16
JMPS
09/26/16
INITIATION
Target $30
JMPS
Outperform
Aimmune initiated with an Outperform at JMP Securities
JMP Securities analyst Liisa Bayko initiated Aimmune with an Outperform and a $30 price target. The analyst is confident that AR101 Phase 3 data will show meaningful desensitization to peanuts in allergic children and adults and we will be paying close attention to safety and any discontinuations and projects $1.4B in sales by 2028.

TODAY'S FREE FLY STORIES

IPXL

Impax

$19.95

-0.85 (-4.09%)

17:55
10/16/17
10/16
17:55
10/16/17
17:55
Hot Stocks
Impax jumps 6% in after-hours after WSJ says Amneal deal near »

Shares of Impax are up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

IPXL

Impax

$19.95

-0.85 (-4.09%)

17:51
10/16/17
10/16
17:51
10/16/17
17:51
Periodicals
Impax and Amneal close to merger pact, WSJ says »

Impax Laboratories and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

AGII

Argo Group

$62.90

-0.25 (-0.40%)

17:36
10/16/17
10/16
17:36
10/16/17
17:36
Hot Stocks
Argo Group provides preliminary Q3 loss estimate »

Argo Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDEF

First Defiance Financial

$53.65

-0.25 (-0.46%)

17:34
10/16/17
10/16
17:34
10/16/17
17:34
Earnings
First Defiance Financial reports Q3 EPS 92c, consensus 89c »

Reports Q3 NII $ $25.0M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

BRO

Brown & Brown

$48.97

-0.42 (-0.85%)

17:33
10/16/17
10/16
17:33
10/16/17
17:33
Earnings
Brown & Brown reports Q3 EPS 53c, consensus 50c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

ORIG

Ocean Rig UDW

$26.18

0.51 (1.99%)

17:31
10/16/17
10/16
17:31
10/16/17
17:31
Hot Stocks
Ocean Rig holder BlueMountain intends to recommend company hire advisers »

Ocean Rig UDW holder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$202.68

3.19 (1.60%)

, IMDZ

Immune Design

$10.10

-0.85 (-7.76%)

17:31
10/16/17
10/16
17:31
10/16/17
17:31
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

NFLX

Netflix

$202.68

3.19 (1.60%)

IMDZ

Immune Design

$10.10

-0.85 (-7.76%)

SAVE

Spirit Airlines

$33.47

-0.33 (-0.98%)

UNH

UnitedHealth

$193.20

0.68 (0.35%)

BMI

Badger Meter

$50.80

-0.6 (-1.17%)

SONC

Sonic

$24.80

0.42 (1.72%)

ABEO

Abeona Therapeutics

$16.70

0.6 (3.73%)

VICL

Vical

$2.86

0.04 (1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 22

    Oct

  • 23

    Oct

  • 08

    Nov

  • 17

    Oct

FDC

First Data

$18.01

0.39 (2.21%)

17:28
10/16/17
10/16
17:28
10/16/17
17:28
Hot Stocks
First Data CAO sells 3,996 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

ROSG

Rosetta Genomics

$1.00

-0.0479 (-4.57%)

17:28
10/16/17
10/16
17:28
10/16/17
17:28
Syndicate
Breaking Syndicate news story on Rosetta Genomics »

Rosetta Genomics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRS

Harris

$135.90

-0.66 (-0.48%)

17:27
10/16/17
10/16
17:27
10/16/17
17:27
Hot Stocks
Harris awarded $100M government contract modification »

Harris Corp., Clifton,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$259.75

-0.99 (-0.38%)

17:26
10/16/17
10/16
17:26
10/16/17
17:26
Hot Stocks
Boeing awarded $240.2M government contract »

The Boeing Co., Oklahoma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

PI

Impinj

$34.98

-0.71 (-1.99%)

17:22
10/16/17
10/16
17:22
10/16/17
17:22
Hot Stocks
Impinj COO sells 7,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 14

    Nov

  • 15

    Nov

ADOM

Adomani

$6.50

-0.36 (-5.25%)

17:21
10/16/17
10/16
17:21
10/16/17
17:21
Syndicate
Breaking Syndicate news story on Adomani »

Adomani files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAVE

Spirit Airlines

$33.47

-0.33 (-0.98%)

17:20
10/16/17
10/16
17:20
10/16/17
17:20
Hot Stocks
Spirit Airlines raises Q3 total RASM view to (6.5%) from (8.5%)-(7%) »

Sees Q3 ASMs up 18%. Sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RESN

Resonant

$4.38

-0.08 (-1.79%)

17:16
10/16/17
10/16
17:16
10/16/17
17:16
Hot Stocks
Breaking Hot Stocks news story on Resonant »

Longboard raises stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$11.85

-0.3 (-2.47%)

17:14
10/16/17
10/16
17:14
10/16/17
17:14
Hot Stocks
Breaking Hot Stocks news story on Caesars »

TPG Group reports 14.3%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

IPSEY

Ipsen

$35.23

1.2 (3.53%)

, EXEL

Exelixis

$29.02

4.26 (17.21%)

17:08
10/16/17
10/16
17:08
10/16/17
17:08
Hot Stocks
Ipsen says Phase 3 Celestial trial of cabozanitinib met primary endpoint of OS »

Before the market opened,…

IPSEY

Ipsen

$35.23

1.2 (3.53%)

EXEL

Exelixis

$29.02

4.26 (17.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 06

    Nov

GOGL

Golden Ocean

$8.50

0.02 (0.24%)

17:06
10/16/17
10/16
17:06
10/16/17
17:06
Syndicate
Golden Ocean files to sell $66M of common stock »

DNB Markets, Arctic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSQ

Townsquare Media

$10.42

0.27 (2.66%)

17:03
10/16/17
10/16
17:03
10/16/17
17:03
Hot Stocks
Townsquare Media appoints Bill Wilson and Dhruv Prasad as co-CEOs »

Townsquare Media has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPX

WPX Energy

$10.90

0.16 (1.49%)

17:03
10/16/17
10/16
17:03
10/16/17
17:03
Initiation
WPX Energy initiated  »

WPX Energy initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

TRQ

Turquoise Hill

$3.36

0.02 (0.60%)

17:02
10/16/17
10/16
17:02
10/16/17
17:02
Hot Stocks
Turquoise Hill sees FY17 Oyu Tolgoi copper production 130K-160K tonnes »

Oyu Tolgoi is expected to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGN

Energen

$53.18

0.3 (0.57%)

17:02
10/16/17
10/16
17:02
10/16/17
17:02
Initiation
Energen initiated  »

Energen initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRQ

Turquoise Hill

$3.36

0.02 (0.60%)

17:02
10/16/17
10/16
17:02
10/16/17
17:02
Hot Stocks
Turquoise Hill reports Q3 Oyu Tolgoi material mined up 9% y/y »

In 3Q17, material mined…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AHL

Aspen Insurance

$41.40

-0.35 (-0.84%)

17:00
10/16/17
10/16
17:00
10/16/17
17:00
Hot Stocks
Aspen Insurance reports preliminary pre-tax hurricane impact of $310M »

Aspen Insurance reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

JAG

Jagged Peak Energy

$13.95

0.03 (0.22%)

17:00
10/16/17
10/16
17:00
10/16/17
17:00
Initiation
Jagged Peak Energy initiated  »

Jagged Peak Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.